Completed NCT04928313

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

A Phase IV, Post-marketing, Prospective, Multicenter Study to Investigate the Safety and Effectiveness of Cinnomer® (Glatiramer-Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Sponsor: Cinnagen

Conditions Relapsing Multiple Sclerosis

Interventions Glatiramer Acetate

Updated 3 times since 2021 Last updated: Jun 13, 2021 Started: Apr 12, 2015 Primary completion: Feb 17, 2020 Completion: Feb 17, 2020

This observational or N/A phase trial investigates Relapsing Multiple Sclerosis and is currently completed. Cinnagen leads this study, which shows 3 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2021 — Jul 2024 [monthly]

Completed

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cinnagen

Data source: Cinnagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.